Skip to main content

BlueWind RENOVA iStim™ System for the Treatment of OAB

Completed · Not applicable · NCT03596671

Conditions: Treatment of Patients Suffering From Overactive Bladder (OAB)

At a glance

Research payments reported, 2025
$140,963
U.S. investigators named
15
Sites paid
11
Planned or actual enrollment
282

About the trial

Sponsor
BlueWind Medical
Tested
RENOVA iStim™ System (device)
Dates
Started 2019-06-12; completion 2025-01-24
Results posted
Yes

The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder.

From ClinicalTrials.gov, last updated 2025-09-16. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Bluewind Medical reported $140,963 in research payments for this study in 2025 (73 payments).

Products named: Revi

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.